Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Legend Biotech (LEGN) Tax Provisions (2019 - 2025)

Legend Biotech filings provide 7 years of Tax Provisions readings, the most recent being -$11.2 million for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 21.13% to -$11.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$14.2 million, a 24.82% increase, with the full-year FY2025 number at -$14.2 million, up 24.87% from a year prior.
  • Tax Provisions hit -$11.2 million in Q4 2025 for Legend Biotech, down from -$616000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $288000.0 in Q3 2023 to a low of -$14.2 million in Q4 2024.
  • Median Tax Provisions over the past 5 years was -$163000.0 (2022), compared with a mean of -$2.0 million.
  • Biggest five-year swings in Tax Provisions: soared 289.47% in 2023 and later plummeted 712236.41% in 2024.
  • Legend Biotech's Tax Provisions stood at -$3.6 million in 2021, then skyrocketed by 95.77% to -$153000.0 in 2022, then skyrocketed by 101.3% to $1994.0 in 2023, then plummeted by 712236.41% to -$14.2 million in 2024, then rose by 21.13% to -$11.2 million in 2025.
  • The last three reported values for Tax Provisions were -$11.2 million (Q4 2025), -$616000.0 (Q3 2025), and -$582000.0 (Q2 2025) per Business Quant data.